The dreadful spread of SARS-CoV-2 virus with its several arbitrarily mutated variants has been a severe global health concern due to the horrendous catastrophic effects on every sector of life across the world (1, 2). Following the declaration of the COVID-19 outbreak as a pandemic on March 11, 2020 by WHO, an ample amount of confirmed cases of the infection and deaths are being reported throughout the world till now (3). As of March 03, 2024, the number of reported confirmed cases is over 77,48,34,251, including 70,37,007 deaths (4). The abundance of the infection is higher in Europe and the Americas than in the Western Pacific and South-East Asia, Eastern Mediterranean, and Africa (4). In Bangladesh, the very first three cases of the SARS CoV-2 infection were confirmed and reported on March 08 2020, by the ‘Institute of Epidemiology, Disease Control and Research (IEDCR)’ (5, 6). Since then, both the rates of infection and death have been increasing across the country. As of March 03 2024, the nationwide numerical value of COVID-19 confirmed cases is 20,48,588, including a total of 29,491 deaths (4).

As a curative measure, several existing allopathic drugs, herbal medicines, and bioactive phytoconstituents found to be somewhat functional against coronavirus disease (2, 7); but yet to achieve herd immunity against COVID-19 vaccines are considered as promising preventive candidates. Because vaccines have been found to be effective against viral infections earlier (8). Therefore, on an emergency basis, to eliminate the spread and catastrophic effects of the novel strains of SARS CoV-2 virus around the world, several vaccines have been licensed worldwide with a short period of development stage (9); including Pfizer (96% efficacy rate), Moderna (94.10% efficacy rate), AstraZeneca-Oxford (70% efficacy rate) and Russian Sputnik V (92% efficacy rate) (10). As of November 26 2023, a total of 13.59 billion doses of different vaccines have been administered worldwide (4). While the Bangladeshi government commenced its nationwide mass vaccination program on February 07, 2021, prioritizing the frontline personnel, doctors, nurses, and older adult people on an initial basis, which is currently applicable for anybody over 18 years old with National Identity Card (10). Notably, the government also brought a massive number of students under vaccination coverage to resume the regular educational scheme after an extensive lockdown phase, which was imposed in the earlier days of the pandemic (10). As of November 26, 2023, in Bangladesh, a total of 15,15,04,394 vaccine doses have been administered nationwide (4); which include five different vaccines, namely, AstraZeneca (Covishield), Pfizer-BioNTech, Sinopharm, Moderna and Sinovac (Coronavac) (4).

Bangladesh began an extensive mass vaccination campaign for anyone above 18 with a national identity to deliver immunizations to university students (11). Despite significant advances in vaccination rollouts, vaccine hesitancy remains a key concern and a barrier to mass immunization success (12, 13). Vaccine reluctance and acceptance are multifaceted, and vaccine responses might differ depending on context, time, vaccine type, and geographical location (14). Despite the availability of vaccination services, vaccine hesitancy is defined as a delay in accepting or avoiding immunization (15). Hence, the precise causes of vaccination apprehension are unknown (16). However, the rate of acceptance or reluctance to take COVID-19 vaccination among Bangladeshis is different from that of other countries due to a lack of public awareness about the efficacy of these novel vaccines, the availability of several different manufacturer’s vaccines, the spread of controversial news in media, mistrust, misconception and cultural, religious, gender or other contemporary socioeconomic factors (17, 18).

For the implementation and estimation of the effectiveness of a nationwide mass vaccination campaign, we need to analyze and study the knowledge, thoughts, attitudes, responses, and opinions of the country’s common people about vaccination (19). Though several considerable survey researches regarding progression and perceptions of pre-and post-vaccination programs at times have been conducted on diversified common Bangladeshi people (11, 17, 20), surveys including the resident and non-resident university students can hardly be found. In addition, the public health sector demands more permutated survey studies in order to ensure broader community uptake of vaccines.

Therefore, this study’s core and primary objective was to explore the behavioral measurements and perceptions regarding COVID-19 vaccination of Bangladeshi undergraduate and post-graduate students of different ages, genders, religions, regions, and lifestyles from different universities across the country. The secondary objective of the study was to estimate the possible side effects of vaccination among the participants along with its relationship with the participant’s gender. Hopefully, the findings of this study will help the country’s respective legislators correlate the public health sector with the education sector.

No patients were involved in this study.

Among the participants, the majority fall in the age group of 22 to 24 years, which is 52%. Others fall into the age group of 18 to 21 years (36.4%), and rest of the participants are older than 25 years old (11.6%). 59% of respondents are male, while the remaining 41% are female. Islam is the most widely followed religion (86.9%), and 13.1% of respondents are from other religions. People partaking in the survey are mostly living with their families (55.9%), and 44.1% of the participants have made their living arrangements on their own. Most of the participants (87.7%) are either undergrads or graduates, and the rest have postgraduates’ degrees or other qualifications. Table 1 presents additional significant demographic characteristics of respondents. Fifty-six percent of the respondents have a good history of health, 35.2% have suffered from allergy diseases, and very few people had asthma, diabetes, heart disease, hypertension, or tuberculosis. 71.6% of the contributors did not test for COVID-19 as there were no symptoms, whereas 13.5% of the respondents did not test but had all the symptoms. 9.6% and 5.3% of people tested negative and positive for COVID-19, respectively. As most of the people did not test for COVID-19, the recovery period is not applicable to them, but 5.4% of participants have taken 1 to 3 days to fully recover, and 2% of people have taken more than 3 days to recover. 84.4% of the respondents have taken at least one dose of the vaccine; 226 completed the first dose, and 756 took both doses. Most of the participants who have taken the vaccine have taken Sinopharm, which is 56.5%. 63.4% of the total participants did not maintain at least 1.5 meters of social distancing, whereas the rest of the 36.6% maintained it. The majority of the respondents (85.5%) have continued to wear a face mask or shield. 73.5% of the participants have not continued washing or sanitizing their hands. 63.4% of the respondents covered their noses and mouths while coughing and sneezing. It is observed that 68.1% of the respondents did not experience any physical or mental illness after taking the first dose of the vaccine, and the remainder have faced either one or more illnesses.

After the first dose of the vaccine, there was no experience of pain and edema (78.4%), headache (85.5%), or increased body temperature (79.7%). There was no loss of appetite (98.4%) or allergy (97.9%). Few people have experienced allergy symptoms after taking the first dose.

Among other medical statuses, there was no experience of rash or itching on the skin (98.7%), no imbalance or lethargic behavior (99.2%), no high blood pressure (99.3%), and no low blood pressure problem (98.7%). Among the mental conditions, 97.7% did not feel any anxiety, and 94.7% had no uneasy feelings or tension.

As a result of all these medical conditions, 78.7% of the participants did not take any medicine for the side effects after taking the first dose of the vaccine, and 21.3% of the respondents have taken either one or more medicines to mitigate the side effects. Most (92.2%) of the participants have not taken any painkiller, and almost everyone (99.6%) has not taken any sedative after taking the first dose of the vaccine. No use of anti-allergic medicine (98.9%), fever medicine (84.4%), or high blood pressure medicine (99.7%) was seen among the respondents.

16.5% of the participants reported at least one kind of mental or physical illness, but the majority reported no such problems (53.7%) after taking the second dose of the vaccine. Among medical conditions after taking the second dose of the vaccine, no pain and edema (92.5%), no headache (92.7%), no rise in body temperature (91.2%), no loss of appetite (99.2%), and no anxiety (99.3%) were seen among the participants. Almost everyone who took the second medicine reported no rash, itching (99.2%), or abnormally low blood pressure (99.7%). As a result, the no fever medicine (91.9%) and no painkiller and anti-allergic medicine (98.9%) intake was very high after the second dose. The vast majority (98.9%) reported no admission to the hospital or I.C.U. after taking any dose of the vaccine after being infected with COVID-19.

Table 2 shows a significant difference in side effects between male and female participants with a previous history of COVID-19 infection after each dose of the vaccine. Analysis shows that female participants experience side effects more than male participants in both the first and second doses. There was a significant difference in the number of patients reporting pain and edema (18.6% male and 25.9% female) after receiving the first and second doses of the vaccine (males 5.2% and females 10.8%). Moreover, the result shows a significant (p = 0.016) difference in the headache for gender (males 12.4% and females 17.4%) in the first dose but no significant (p = 0.279) difference after the second dose. There is a significant association between gender and increased body temperature (p = 0.008 for the first dose and p = 0.005 for the second dose) after each dose of the vaccine. In both cases, increased body temperature is reported mostly by female participants. It is also seen that there is a significant (p = 0.003) symptom of appetite loss from males (0.7%) to females (2.9%) in the first dose, although there is no significant (p = 0.372) difference between males (0.6%) and females (1.0%) after the second dose.

Rash or itching showed a significant association after the first and second doses. Furthermore, in the case of allergy, imbalance, high blood pressure, low blood pressure, anxiety, or an uneasy feeling, there is no significant difference between males and females for either of the doses.

Table 3 presents the students’ information regarding the side effects of different types of vaccines. It is visible that both doses of the Moderna vaccine are significantly associated with the reporting of pain and edema and increased body temperature symptoms compared to the Covishield, Pfizer, Sinopharm, and Sinovac vaccines. More than half of the participants receiving the Moderna vaccine have reported pain, edema, and increased body temperature after the vaccination. Other vaccines, such as Covishield, Sinopharm, and Pfizer, showed mild side effects after vaccination.

Table 4 represents the binary logistic predictors of COVID-19 vaccine side effects after the first dose. In the binary logistic regression model, the age group 22–24 has 1.335 times (aOR: 1.335, 95% CI: 1.012–1.763) higher odds of experiencing the side effect of COVID-19 vaccine than the age group 18–21. Female students are significantly 11.6% (aOR: 1.116, 95% CI: 0.846–1.472) more likely to experience any side effect of the COVID-19 vaccine than males. The table shows that students living in urban areas have 1.471 times (aOR: 1.471, 95% CI: 1.059–2.045) higher odds of experiencing side effects after the first dose than rural-based students.

Also, students living in suburban areas have 1.510 times (aOR: 1.510, 95% CI: 1.023–2.231) higher odds of experiencing side effects than rural respondents. Living arrangements have no impact on the side effects of the COVID-19 vaccine since they are statistically insignificant.

Table 4 also shows that postgraduate students are 1.565 times (aOR: 1.565, 95% CI: 1.009–2.428) more likely to experience the side effect of the COVID-19 vaccine than undergraduate students, with a p-value of 0.046. Health status and living arrangements have no impact on the side effects of the COVID-19 vaccine since the findings are not statistically significant.

Compared to students who did not contract SARS-CoV-2, those who did are 1.613 times (aOR: 1.613, CI: 1.178 to 2.207) more likely to experience any side effects following the initial dose. The recovery period is a significant factor; those students who needed 1–3 days to recover are 4.615 times (aOR: 4.615, 95% CI: 2.642–8.060) more likely to experience side effects after the first dose. Students who require more than 3 days to recover from COVID-19 are 4.172 times (aOR: 4.172, 95% CI: 1.722–10.107) more likely to experience side effects (p-value = 0.002). Allergy is a significant factor for side effects; respondents with allergies are 1.327 times (aOR: 1.327, 95% CI: 1.020–1.726) more likely to experience side effects after the first dose. Those who maintain a social distance of at least 15 meters in public spaces are 0.669 times (aOR: 0.669, 95% CI: 0.501–0.893) less likely, or 33.1% less likely, to experience any side effect of the COVID-19 vaccine after the first dose. Covering the mouth and nose when coughing and sneezing made people 1.557 times (aOR: 1.557, 95% CI: 1.158–2.094) more likely to experience side effects (p = 0.003).

This study aimed to assess the perceptions and experiences of university students regarding the side effects of the COVID-19 vaccines in Bangladesh. The participants experienced different physical and mental illnesses after receiving the doses of the COVID-19 vaccine. This study shows that four out of five (84.4%) participants have taken at least one dose of any of the COVID-19 vaccines available for university students in Bangladesh. Some participants experienced pain and edema, growing body temperature, and headache after receiving the first dose, while very few reported uneasy feelings and tension after receiving the first dose. Likewise, after receiving the second dose, a few participants encountered body temperature, pain, edema, and headache. A similar result was found in a study in Bangladesh that observed a wide range of adverse side effects, such as fever, headache, and pain, where the vaccine was injected, which aligns with our study (23). Some other research revealed that the side effects caused by the COVID-19 vaccines are pain where the vaccine was injected, muscle pain, joint pain, fever, headache, tiredness, and fatigue (24–26), thus complementing the findings of our study. Usually a non-serious adverse event like pain, headache, and injection site pain are reported for every million doses administered (27). Injection site pain, headache, or fatigue was also common for 50% of participants in the clinical trial (28). The reported adverse effects after the first dose were non-serious and temporary in Bangladesh (9). From our study, it is also evident that the participant’s sex was substantially associated with the side effects of the COVID-19 vaccine after receiving both doses. Female participants were more likely to suffer from the general side effects than their male counterparts, which resembles previous studies (24, 29–33). Still, some contradictory results were found where no sex difference regarding the effects of the COVID-19 vaccine was reported among the vaccine recipients (34, 35). This may be due to information biases, as women are more likely to report their experiences than men (31). Besides, the difference between sex and endocrine hormones may play important roles in the higher report of side effects of the COVID-19 vaccine (36). Another reason may be that women are more susceptible to adverse events of pharmacokinetics and pharmacodynamics, or women may carry a significant percentage of body fat compared to men (37). The present study also suggested a significant relationship between different (symptoms) adverse effects and sex after receiving doses of the COVID-19 vaccine. For example, female students most likely suffered from pain, edema, and body temperature compared to male students. To the best of our knowledge, our study’s unique findings determined the association between sex and the specific type of adverse effects of COVID-19 vaccination.

This study uncovered another important aspect of COVID-19 vaccination, suggesting a significant association between vaccine types and side effects after vaccination (at least taking one of the doses). It was found that the majority of the participants received the Sinopharm vaccine, while others received Moderna, Covishield, and Pfizer-BioNTech vaccines. However it is seen that the first and second dose of the Moderna vaccine was significantly associated with higher reports of pain, edema, and body temperature symptoms compared to Covishield, Pfizer, Sinopharm, and Sinovac vaccines. More than half of the participants who received the Moderna vaccine reported feeling pain and body temperature after receiving it. This is similar to the findings of previous studies (32, 38–40). A possible reason for this outcome may be an inactive substance that serves as the vehicle or medium for other active agents utilized in the mRNA vaccine (Moderna). This agent serves as prevention against bacterial infections by invigorating a more grounded immune reaction, which may have significantly contributed to prompt reactions related to vaccination (41). Some of the other causes of these side effects may be due to a pre-existing physical problem (e.g., prior history of asthma, food or drug allergies), or it may be an unfortunate coincidence limited by medical science and has no relation with vaccination (42).

From binary logistic regression, some important predictors of side effects of the COVID-19 vaccine were identified. Female students were more likely to experience side effects of the COVID-19 vaccine than male students. Similar results were found in studies conducted in other countries, such as Saudi Arabia, Israel, the USA, Japan, and UAE (29–33, 36, 43). This study found that the participants with prior COVID-19 infection were more likely to experience side effects after taking the first dose. A cross-sectional study in the USA among healthcare workers with similar results acknowledged that the adverse reaction of the post-vaccination period was more prevalent among people who were infected by COVID-19 previously (42).

The age of the participants was another significant predictor of the possibility of experiencing adverse reactions after vaccination. Higher odds of side effects of the COVID-19 vaccine were found in the age group 22–24 compared to the age group 18–21, and this result is parallel with the findings of previous clinical trials in the Czech Republic, India, and Pakistan (37, 44, 45). The receptivity of the vaccine producing usual prospective adverse reactions declined with age as per these studies (37, 44, 45). However, it is not a possible cause of a desired resistant reaction (46).

We found inconsistent results demonstrating age as an independent predictor of the vaccine’s side effects (47). Another study claimed that they could not imbed a relationship between the vaccine’s adverse effects and age (48). A significant relationship was observed between the students having allergies and the side effects of the COVID-19 vaccine after the first dose. The participants with allergies were more likely to experience adverse effects after taking the first dose of the COVID-19 vaccine than those with no history of allergy. Some previous studies support this finding that the allergic history of the participants is usually the associated reason for adverse reactions to the COVID-19 vaccine (29, 38, 49, 50).

To the best of the authors’ knowledge, this is the first study to investigate the side effects of several COVID-19 vaccines among university students in Bangladesh. Previous studies on this particular topic focused mostly on healthcare workers and general people. Since university students are educated and adults, their responses recorded are mostly reliable. However, the study has several limitations too. Due to the convenience sampling approach, there might be some selection biases. Second, since the study was online, voluntary, and self-administered, we cannot confirm the seriousness of all participants while filling out the e-questionnaire, causing potential information bias. Third, the study participants are limited to university students aged 18–30, which may restrict generalization of the findings for other age groups. Fourth, the survey is online based so a group of students might miss the opportunity to be included in the survey due to lack of online facilities. Fifth, we do not have any information after the third, fourth or other consecutive doses of the vaccines, which might reflect a different scenario. Future studies should try to address these issues with more inclusive analysis and data collection strategies.

The COVID-19 vaccination effectively protects against fatal disease, hospitalization, and death. However, the recipients reported a wide range of side effects, which may not be severe or fatal. It is reported that side effects (pain and edema, body temperature, and headache) were reported mainly by recipients of Moderna, while recipients of other vaccines (Covishield, Sinopharm, and Pfizer) also showed side effects after vaccination, though they were mild (allergies, anxiety, and uneasy feelings). Side effects were mainly reported after the first dose of the COVID-19 vaccination. Side effects of the COVID-19 vaccine varied between sexes, previous infection status, and individuals with allergy issues. Finally, this study’s findings might help policymakers choose the vaccine for the mass population with minimal side effects.

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/NIIRDQ.

The studies involving humans were approved by Khulna University Ethical Clearance Committee (Protocol Number – KUECC-2021/11/32). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their online informed consent to participate in this study. Online informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Moreover, the participants were free to decline the online survey without providing any prior explanation.

MAI: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Supervision, Writing – original draft, Writing – review & editing. MTN: Data curation, Formal analysis, Methodology, Software, Writing – original draft. AR: Investigation, Writing – original draft, Writing – review & editing. ASMMAH: Data curation, Investigation, Writing – original draft. UJJ: Data curation, Investigation, Writing – original draft. TT: Data curation, Investigation, Writing – original draft. SDB: Data curation, Investigation, Methodology, Writing – original draft. ST: Data curation, Investigation, Writing – original draft. AAM: Data curation, Investigation, Writing – original draft. SP: Data curation, Investigation, Writing – original draft. JN: Data curation, Investigation, Writing – original draft. RaWA: Writing – review & editing, Funding acquisition, Resources. ReWA: Resources, Writing – review & editing. MTH: Conceptualization, Validation, Writing – review & editing, Supervision.